JPS5920217A - Aqueous jellylike composition stably containing urea - Google Patents
Aqueous jellylike composition stably containing ureaInfo
- Publication number
- JPS5920217A JPS5920217A JP13074982A JP13074982A JPS5920217A JP S5920217 A JPS5920217 A JP S5920217A JP 13074982 A JP13074982 A JP 13074982A JP 13074982 A JP13074982 A JP 13074982A JP S5920217 A JPS5920217 A JP S5920217A
- Authority
- JP
- Japan
- Prior art keywords
- urea
- composition
- ammonium
- aqueous
- carboxyvinyl polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title claims abstract description 54
- 239000004202 carbamide Substances 0.000 title claims abstract description 54
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 17
- 150000003868 ammonium compounds Chemical class 0.000 claims abstract description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002585 base Substances 0.000 claims abstract description 10
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims abstract description 3
- 235000015110 jellies Nutrition 0.000 claims description 20
- 239000008274 jelly Substances 0.000 claims description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 3
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 2
- 239000005695 Ammonium acetate Substances 0.000 claims description 2
- 239000004251 Ammonium lactate Substances 0.000 claims description 2
- 239000004254 Ammonium phosphate Substances 0.000 claims description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 235000019257 ammonium acetate Nutrition 0.000 claims description 2
- 229940043376 ammonium acetate Drugs 0.000 claims description 2
- 229940059265 ammonium lactate Drugs 0.000 claims description 2
- 235000019286 ammonium lactate Nutrition 0.000 claims description 2
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 claims description 2
- 229910000148 ammonium phosphate Inorganic materials 0.000 claims description 2
- 229940010556 ammonium phosphate Drugs 0.000 claims description 2
- 235000019289 ammonium phosphates Nutrition 0.000 claims description 2
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 16
- 238000000354 decomposition reaction Methods 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 8
- 102000011782 Keratins Human genes 0.000 abstract description 6
- 108010076876 Keratins Proteins 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000003513 alkali Substances 0.000 abstract description 2
- 150000007514 bases Chemical class 0.000 abstract description 2
- 239000003906 humectant Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 206010020649 Hyperkeratosis Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 208000001126 Keratosis Diseases 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- -1 carboxyvinyl Chemical group 0.000 description 2
- 239000000490 cosmetic additive Substances 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は、薬用または化粧用基剤として有用な、安定に
尿素・を配合した水性ゼリー状組成物に関するものであ
る。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an aqueous jelly-like composition stably containing urea, which is useful as a medicinal or cosmetic base.
尿素は生体内に存在し、蛋白のポリペプチドに変化を与
える結果その可溶性を増大させ、抗菌作用、蛋白融解変
性作用、水利的現象すなわち水分保持能力の先進作用、
また特異な性質として皮膚吸収の先進などの皮膚科的に
重要な薬理作用を有する。さらに高濃度の尿素水溶液が
穏やかな角質軟化作用を示すことも知られている。この
ような特徴のある作用を利用した尿素製剤が、近年皮膚
の保湿剤や角質化の進んだ皮膚の治療剤として用いられ
ている。これらの尿素含有製剤において、一般に尿素濃
度が約10wt%以上の場合には皮膚の保湿剤として、
まだ約10wt%以上の場合には角質化の進んだ皮膚、
例えば尋常性魚鱗解などの角化症の治療剤として用いら
れるのが通例であり1、その場合qZW型エマルジョン
として製剤化されでいる。また、尿素の角質軟化作用を
応用した皮1+’i真菌治4f、〈剤も特開昭52−1
0424号公報に開示され°Cいる。Urea exists in living organisms, and as a result of changing protein polypeptides, it increases its solubility, and has antibacterial effects, proteolytic denaturation effects, and advanced water-retaining effects.
It also has unique properties such as advanced skin absorption and other important pharmacological effects in dermatology. Furthermore, it is also known that a highly concentrated urea aqueous solution exhibits a mild keratin softening effect. Urea preparations that take advantage of these characteristic effects have recently been used as skin moisturizers and therapeutic agents for highly keratinized skin. In these urea-containing preparations, when the urea concentration is approximately 10 wt% or more, it is generally used as a skin moisturizer.
If it is still more than about 10 wt%, the skin is highly keratinized,
For example, it is usually used as a therapeutic agent for keratosis such as ichthyosoma vulgaris1, and in this case it is formulated as a qZW type emulsion. In addition, skin 1+'i fungal treatment 4f, which applied the keratin softening effect of urea, was also published in JP-A-52-1.
It is disclosed in Publication No. 0424.
しかし尿素は、べわめて容易に分解してアンモニアを発
生し、基剤のP Hが上昇してしまう。尿素の分解に)
1Q因するP flの上昇は、皮膚のアルカリ中和能に
障害を与え、皮膚の細菌感染を促進するうえ、さらにア
ンモニア臭の発生により商品価値を著しく低トさせてし
まう。そのため尿素は、なかなか製剤化しにくいという
問題点があった。However, urea decomposes very easily and generates ammonia, which increases the pH of the base material. for the decomposition of urea)
The increase in Pfl caused by 1Q impairs the skin's alkali neutralizing ability, promotes bacterial infection of the skin, and furthermore significantly reduces the commercial value due to the generation of ammonia odor. Therefore, urea has had the problem of being difficult to formulate into formulations.
とくに尿素の濃度が高くなるとこの傾向は増大する。In particular, this tendency increases as the concentration of urea increases.
従来、尿素の分解を抑制する方法として、中性アミノ酸
を添加する方法(オース) IJア国特許第23762
5号)、乳酸を加える方法(西ドイツ公開性¥[第19
11144号)、塩化アンモニウムなどのアンモニウム
化合物を添加する方法(特公昭46−1i010号)、
脂肪族ジカルボン酸を添加する方法(特開昭52−10
5225号)、アラントインを添加する方法(特開昭5
2−109487号)、ヒドロキシルアミン鉱酸塩全添
加する方法(特開昭55−122753号)など数多く
の方法が開示されている。しかしこれらの方法は、いず
れもその効果は充分とはいえず、尿素を化粧品や外用薬
に応用して最終的に商品化するのは困難であった。Conventionally, as a method of suppressing the decomposition of urea, a method of adding neutral amino acids (Aus) IJ African Patent No. 23762
No. 5), method of adding lactic acid (West German openness [No. 19
11144), a method of adding ammonium compounds such as ammonium chloride (Japanese Patent Publication No. 46-1i010),
Method of adding aliphatic dicarboxylic acid (JP-A-52-10
No. 5225), method of adding allantoin (Japanese Patent Application Laid-open No. 5
A number of methods have been disclosed, including a method in which hydroxylamine mineral salt is completely added (Japanese Patent Application Laid-open No. 122753/1983). However, none of these methods can be said to be sufficiently effective, and it has been difficult to apply urea to cosmetics or external medicines and ultimately commercialize them.
本発明者らは、尿素を化粧品や外用薬に安定に配合する
のに際し、水性ゼリー状に尿素を製剤化することに着目
して研究を進めた、その理由は、尿素をエマルジ言ン形
に製剤化する場合には、高温に加熱することにより尿素
の分解が促進されること、および乳化剤として多量の界
面活性剤を使用しなければならず界面活性剤に起因する
皮膚への悪影響が避けられないからでおる。The present inventors conducted research focusing on formulating urea in the form of an aqueous jelly in order to stably incorporate urea into cosmetics and external drugs. When formulating urea, heating it to high temperatures accelerates the decomposition of urea, and a large amount of surfactant must be used as an emulsifier to avoid adverse effects on the skin caused by surfactants. It's because there isn't.
本発明者らは、尿素を安定に水性ゼリー状に製剤化する
ことを目的として鋭意検討したところ、特定の尿素分解
抑制剤と水済性高分子を組合わせることにより尿素の分
解が相乗的に抑制されることを見いだし、本発明を完成
させるに至った。The present inventors conducted intensive studies with the aim of stably formulating urea into an aqueous jelly-like formulation, and found that the combination of a specific urea decomposition inhibitor and a water-soluble polymer synergistically inhibits the decomposition of urea. They have found that this can be suppressed and have completed the present invention.
すなわち本発明は、アンモニウム化合物およびカルボキ
シビニルポリ々−を配合し、PH1−5,5〜7.5と
したことを特徴とする尿素を安定に含む水性ゼリー状組
成物に関するものである。That is, the present invention relates to an aqueous jelly-like composition stably containing urea, which is characterized in that it contains an ammonium compound and a carboxyvinyl polyester, and has a pH of 1-5.5 to 7.5.
本発明の水性ゼリー状組成物における尿素の配合量は1
〜48wt%である。尿素の配合量が1wtチ未満では
皮膚への湿潤作用が乏しく、また48tvt%を越えた
場合は尿素の飽和濃度に近づくにつれ低温で尿素の結晶
が析出するようになるので好ましくない。尿素の配合量
が1〜10wt%程度の場合は角質軟化作用は弱いため
、保湿作用を有する化粧品の水性ゼリー状基剤として応
用することができる。尿素の配合量が10wt%を越え
る場合は、角質化した皮膚の軟化作用を利用して、外皮
作用−トの基剤とすることができる。The amount of urea in the aqueous jelly composition of the present invention is 1
~48wt%. If the amount of urea is less than 1wt%, the moisturizing effect on the skin will be poor, and if it exceeds 48tvt%, urea crystals will precipitate at low temperatures as the urea saturation concentration approaches, which is not preferable. When the amount of urea is about 1 to 10 wt%, the keratin softening effect is weak, so it can be applied as an aqueous jelly base for cosmetics with a moisturizing effect. When the blending amount of urea exceeds 10 wt%, it can be used as a base for a skin-acting agent by utilizing its softening effect on keratinized skin.
本発明で用いられるアンモニウム化合物は、塩化アンモ
ニウム、硫酸アンモニウム、硝酸アンモニウム、リン酸
アンモニウム、酢酸アンモニラ人乳酸アンモニウムおよ
びシュウ酸アンモニウムである。アンモニウム化合物の
添加量は、0.5〜5鐵4である。アンモニウム化合物
の添加量が0.5wt%未満の場合は、尿素の分解抑制
剤としての効果がきわめて弱くなり、5帆チを越えて配
合すると水性ゼリー状組成物の耐寒性が低下するため好
ましくない。The ammonium compounds used in the present invention are ammonium chloride, ammonium sulfate, ammonium nitrate, ammonium phosphate, ammonium acetate, ammonium lactate and ammonium oxalate. The amount of ammonium compound added is 0.5 to 5 parts. If the amount of ammonium compound added is less than 0.5 wt%, the effect as a urea decomposition inhibitor will be extremely weak, and if it is added in more than 5 parts, the cold resistance of the aqueous jelly composition will decrease, which is not preferable. .
本発明組成物で用いられるカルボキシビニルポリマーは
分子量が、1,000,000〜3,000,000程
度のものが好ましく、その配合量は0.5〜5 wt
%が適当である。カルボキシビニルポリマーの配合量が
0、5 wt To未滴の場合は、ゼリー状を保つこと
が困難であり、とくに高温に保存したときに流動性の高
い液状となり好ましくない。一方配合量がSwtチを越
えると、ゼリー状態が固くなりすぎるため好ましくない
。The carboxyvinyl polymer used in the composition of the present invention preferably has a molecular weight of about 1,000,000 to 3,000,000, and its blending amount is 0.5 to 5 wt.
% is appropriate. If the amount of carboxyvinyl polymer blended is 0.5 wt To, it is difficult to maintain a jelly-like state, and especially when stored at a high temperature, the product becomes a liquid with high fluidity, which is not preferable. On the other hand, if the blending amount exceeds Swt, the jelly state becomes too hard, which is not preferable.
本発明組成物において、PHを5,5〜7.5に調整す
るためのPH調整剤としては、水酸化ナトリウム、水酸
化カリウムなどのアルカリ金属の水酸化物、モノエタノ
ールアミン、ジエタノールアミン、トリエタノールアミ
ンなどのアルカノールアミン、リジン、アルギニン、オ
ルニチンなどの塩基性アミノ酸およびアンモニアなどの
塩基性化合物があげられる。PHが5.5未満であると
カルボキシビニルポリマーの増粘効果がでずゼリー状と
ならない。PHが7.5を越えると尿素の分解が促進さ
れ好凍しくない。In the composition of the present invention, examples of the pH adjusting agent for adjusting the pH to 5.5 to 7.5 include alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, monoethanolamine, diethanolamine, and triethanolamine. Examples include alkanolamines such as amines, basic amino acids such as lysine, arginine, ornithine, and basic compounds such as ammonia. If the pH is less than 5.5, the carboxyvinyl polymer will not have a thickening effect and will not become jelly-like. When the pH exceeds 7.5, the decomposition of urea is promoted and freezing is not good.
本発明組成物は、前記のアンモニウム化合物とカルボキ
シビニルポリマーを併用し、PHを5.5〜7.5と調
整することにより尿素の分解を抑制することを特徴とす
るが、この尿素の分解抑制は各成分の組合せの相乗効果
により達成されるもので・らる。したがって、カルボキ
シビニルポリマーのみ配合しP l(を5.5〜7,5
に調整した場合や、カルボキシビニルポリマーの代りに
他の水溶性高分子とアンモニウム化合物を併用してP
I(’fr: 5.5〜75に調整した場合などのよう
に本発明の檜成要「トのいずれかを欠いたものは、尿素
の安定性が本発明組成物より劣る。本発明組成物の各成
分はいずれも公知なものであるが、それらの相乗効果に
よる尿素の安定化は従来技術から予知しえないものであ
る。The composition of the present invention is characterized by suppressing the decomposition of urea by using the above-mentioned ammonium compound and carboxyvinyl polymer in combination and adjusting the pH to 5.5 to 7.5. is achieved through the synergistic effect of the combination of each component. Therefore, by blending only carboxyvinyl polymer, P l (5.5 to 7.5
or by using other water-soluble polymers and ammonium compounds in place of carboxyvinyl polymers.
If the cypress composition of the present invention lacks any of the essential points, such as when adjusted to I('fr: 5.5 to 75), the stability of urea is inferior to the composition of the present invention.The composition of the present invention Although each component of the product is known, the stabilization of urea due to their synergistic effect could not be predicted from the prior art.
本発明組成物中の尿素が安定に存在する理由は明らかで
はないが、カルボキシビニルポリマー中のカルボキシル
基とアンモニウム化合物の相互作用により原電が安定化
されるものと思われる。Although the reason why urea stably exists in the composition of the present invention is not clear, it is thought that the raw electricity is stabilized by the interaction between the carboxyl group in the carboxyvinyl polymer and the ammonium compound.
本発明組成物を製造する方法の一例を示すと、カルボキ
シビニルポリマー、PH調整剤および水を約80℃に加
熱溶解し充分に混合した後、50〜60℃まで冷却し、
尿素とアンモニウム化合物を加え混合すると水性ゼリー
状組成物が得られる。An example of the method for producing the composition of the present invention is to heat and dissolve the carboxyvinyl polymer, PH adjuster, and water at about 80°C, mix thoroughly, and then cool to 50 to 60°C.
When urea and ammonium compound are added and mixed, an aqueous jelly-like composition is obtained.
本発明の水性ゼリー状組成物は、尿素濃度が10wt%
を越えるものはそのままで尋常性魚鱗病やアトピー皮膚
などの角化症の治療剤とすることもできるが、化粧料ま
たは外用薬の基剤として最適である。すガわち、本発明
の水性ゼリー状組成物を基剤として、保湿剤、紫外線吸
収剤、香料、着色料、防腐剤などの常用の化粧料添加剤
や、薬剤を加えて、尿素の湿潤作用や角質軟化作用を利
用した特徴のあるゼリー状の化粧品や外用薬とすること
ができる。とくに本発明組成物全外用薬に応用するには
、塩化ベンザルコニウム、クロトリマゾール、ビロール
ニドリン、トルナフテート、ウンテシレン酸などの抗真
菌剤、塩酸シフ・ンヒドラミンなどの抗ヒスタミン剤、
消炎剤などの薬剤を加えて、皮膚白解症(水虫)治療剤
、角化在治療剤、かゆみ市め、などの皮膚疾患治療薬を
得ることができる。The aqueous jelly composition of the present invention has a urea concentration of 10 wt%.
Those exceeding 20% can be used as therapeutic agents for keratosis such as ichthyosis vulgaris and atopic skin, but they are most suitable as bases for cosmetics or external medicines. Specifically, the aqueous jelly-like composition of the present invention is used as a base, and commonly used cosmetic additives and drugs such as humectants, ultraviolet absorbers, fragrances, colorants, and preservatives are added to moisten the urea. It can be made into jelly-like cosmetics or external medicines that take advantage of its keratin softening and keratin softening effects. In particular, in order to apply the composition of the present invention to all external medicines, antifungal agents such as benzalkonium chloride, clotrimazole, virolnidoline, tolnaftate, and untesylenic acid, antihistamines such as Schiff-nhydramine hydrochloride,
By adding drugs such as anti-inflammatory agents, it is possible to obtain therapeutic agents for skin diseases such as skin albinism (athlete's foot) treatment, hyperkeratosis treatment, and itching treatment.
これらの化粧オ」添加剤や薬剤のうち水に不溶性のもの
を配合する場合は、適尚な溶媒中に必要に応じて界面活
性剤を用いてあらかじめ溶解または分散させたものを配
合すればよい。When blending water-insoluble cosmetic additives and drugs, they may be dissolved or dispersed in an appropriate solvent using a surfactant as necessary. .
さらに本発明の組成物にその他の成分、たとえd゛ゼリ
ー硬さを調整するための粘度調整剤や、P Hをさらに
安定させるためのP H緩衝剤などを加えてもよい。Furthermore, other ingredients may be added to the composition of the present invention, such as a viscosity modifier to adjust the jelly hardness and a PH buffer to further stabilize the PH.
さらに本発明を実施例により詳細に説明する。Further, the present invention will be explained in detail with reference to Examples.
実施例1.2、比較例1〜4
第1表に示したA群の配合物を約80℃に加熱混合した
後50〜60℃まで冷却し、B群の配合物を加えて水性
ゼリー状組成物を得た。ただし比較例1の中和剤を加え
ない組成物は粘度が低く、ゼリ「状とならなかった。こ
うして得た水性ゼリー状組成物を40℃に保存しで、!
i日後、10日後、15日後、30日後のP Hを測定
し、尿素の安定性を調々た。その結果全第1表に示す。Example 1.2, Comparative Examples 1 to 4 The formulations of group A shown in Table 1 were heated and mixed at about 80°C, then cooled to 50 to 60°C, and the formulations of group B were added to form an aqueous jelly. A composition was obtained. However, the composition of Comparative Example 1 without the addition of a neutralizing agent had a low viscosity and did not form a jelly-like composition.The aqueous jelly-like composition thus obtained was stored at 40°C and...
PH was measured after i days, 10 days, 15 days, and 30 days to examine the stability of urea. The results are shown in Table 1.
第1表の結果から明らかなように、カルボキシビニルポ
リマーと塩化アンモニウムを併用し、さらにPHを調整
した本発明組成物中の尿素が安定なのに対し、本発明構
成要件のいずれかを欠く比較例はすべて尿素の分解が進
行し、アンモニア臭が発生した。As is clear from the results in Table 1, the urea in the composition of the present invention in which carboxyvinyl polymer and ammonium chloride are used in combination and the pH is adjusted is stable, whereas the comparative example lacking any of the constituent elements of the present invention is stable. Decomposition of urea progressed in all cases, and an ammonia odor was generated.
以1余白
第 1 表
註l) カーポボール941(商品名、グツドリッチ社
製、分子量1.000.(100〜1,500,000
)を用いた実施例3〜7
第2表に示す組成の配合物を実施例1に準じて処理を行
ない、水性ゼリー組成物を得た。このものを40℃に3
0日間保存した後、PHを測定し尿素の安定性を調べた
。その結果を第2表に示す。1 margin, 1st table note l) Carpoball 941 (trade name, manufactured by Gutdrich, molecular weight 1.000. (100-1,500,000)
) Examples 3 to 7 Using the compositions shown in Table 2, the formulations shown in Table 2 were treated according to Example 1 to obtain aqueous jelly compositions. Heat this to 40℃ for 3
After storage for 0 days, the pH was measured to examine the stability of urea. The results are shown in Table 2.
第 2 表
第2表の結果から本発明組成物は尿素が低濃度から高濃
度の範囲で安定であることが明らかである。Table 2 From the results shown in Table 2, it is clear that the composition of the present invention is stable in the range of urea concentration from low to high.
実施例7〜10
実施例1の水性ゼリー状組成物の塩化アンモニウムを第
2表に示した他のアンモニウム化合物に代えた以外は実
施例1に県じて水性ゼリー状組成物を慴た1、このもの
を40℃に30日間保存した後、Pllをdlll定し
、尿素の安定性を調べた。その結果を第3表に示す。Examples 7 to 10 Aqueous jelly compositions were prepared in the same manner as in Example 1, except that ammonium chloride in the aqueous jelly composition of Example 1 was replaced with other ammonium compounds shown in Table 2. After storing this product at 40°C for 30 days, Pll and dllll were determined and the stability of urea was examined. The results are shown in Table 3.
第 3 表
第3表の結果から明らかなよりn−本発明の水性ゼリー
状組成物は、40℃に30日間保存しても尿素が分1宵
−jることかなく、ゼリーの粘度も変化しなかった。Table 3 It is clear from the results in Table 3 that the aqueous jelly composition of the present invention does not lose urea even when stored at 40°C for 30 days, and the viscosity of the jelly does not change. I didn't.
参考例1 ハンドゼリーのill製
第4表に示す組成のA群を約80℃に加熱混合し、カル
ボキシビニルポリマーを均一に溶解させ整して冷却した
。こうして得たノ・ンドゼリーは、使用感にすぐれたエ
モリエント効果の高いものであった。Reference Example 1 Hand jelly manufactured by Ill Group A having the composition shown in Table 4 was heated and mixed at about 80° C., and the carboxyvinyl polymer was uniformly dissolved and prepared, and then cooled. The thus obtained No.Ndo jelly was easy to use and had a high emollient effect.
第 4 表
参考例2 角化症治療剤の調製
第5表に示す組成のA群を約80℃に加熱混合し、カル
ボキシビニルポリマーを均一に溶解させた後、約60℃
に温度を下げ尿素を加え、最後にリジンでPI■を調整
して冷却した。こうして得た水性ゼリー状組成物は、尋
常性魚鱗病などの角化症の治療剤として有効であった。Table 4 Reference Example 2 Preparation of a therapeutic agent for keratosis Group A having the composition shown in Table 5 was heated and mixed at about 80°C to uniformly dissolve the carboxyvinyl polymer, and then heated to about 60°C.
The temperature was lowered and urea was added, and finally PI was adjusted with lysine and cooled. The aqueous jelly-like composition thus obtained was effective as a therapeutic agent for keratosis such as ichthyosis vulgaris.
第 5 表
註2) カーボボール940(商品名、ダッドリ、チ社
製、分子量2.000,00 Q〜3,000,000
)を用いた。Table 5 Note 2) Carboball 940 (trade name, Dudli, manufactured by Chi Co., Ltd., molecular weight 2.000,00 Q - 3,000,000
) was used.
参考例3 皮膚真菌症治療剤の調製
第6表に示す組成のA群を約80℃に加熱混合し、カル
ボキシビニルポリマーを均一に溶解した後、約60℃に
温度を下げB群の配合物を加え、さらにあらかじめ加熱
溶解しておいた0群を少しずつ加えた。最後にDの中和
剤を加えてP Hを調整して冷却した。得られた水性ゼ
リー状組成物は、皮膚真菌症の治療に効果が認められた
。Reference Example 3 Preparation of therapeutic agent for skin mycosis Group A having the composition shown in Table 6 was heated and mixed at about 80°C to uniformly dissolve the carboxyvinyl polymer, and then the temperature was lowered to about 60°C and the mixture of Group B was prepared. was added, and Group 0, which had been heated and dissolved in advance, was added little by little. Finally, neutralizing agent D was added to adjust the pH and the mixture was cooled. The resulting aqueous jelly composition was found to be effective in treating skin mycosis.
第 6 表
参考例1〜3の水性ゼリー状組成物に含まれる尿素の安
定性を調べるために、各水性ゼリー状組成物の調製直後
および40℃に30日間保存後のI’Hを測定(測定温
度25℃)した。その結果を第7表に示す、。In order to investigate the stability of urea contained in the aqueous jelly compositions of Reference Examples 1 to 3 in Table 6, the I'H of each aqueous jelly composition was measured immediately after preparation and after storage at 40°C for 30 days ( The measurement temperature was 25°C). The results are shown in Table 7.
第 7 表
参考例1〜3の水性ゼリー状組成物は、いずれもアンモ
ニア臭がなく、PHの上昇も低いことから、尿素の分解
が抑制されていることは明らかである。。The aqueous jelly compositions of Reference Examples 1 to 3 in Table 7 all have no ammonia odor and have low pH increases, so it is clear that the decomposition of urea is suppressed. .
Claims (1)
ンモニウム化合物およびカルボキシビニルポリマーを配
合し、PHを5.5〜7.5としたこと全特徴とする尿
素を安定に含む水性ゼリー状組成物。 2、 アンモニウム化合物が0.5〜5 wt % 、
およびカルボキシビニルポリマーが0.5〜5 wt
To配合される特許請求の範囲第1項記載の組成物。 3、 アンモニウム化合物が、塩化アンモニウム、硫酸
アンモニウム、硝酸アンモニウム、リン酸アンモニウム
、r酢f俊アンモニウム、乳酸アンモニウムおよびシュ
ウ酸アンモニウムから選ばれる特許請求の範囲第1項記
載の組成物。 4 カルボキシビニールポリマーの分子量が、1.00
(1,(100〜3.0旧)、000である特許請求
の範囲第1項記載の組成物。 5、PHがアルカリ金属の水酸化物、アルカノールアミ
ン、塩基性アミノ酸およびアンモニアから選ばれる塩基
によって調整される特許請求の範囲第1項記載の組成物
。[Scope of Claims] 1. An aqueous composition containing 1 to 48 wt% of urea, which contains an ammonium compound and a carboxyvinyl polymer and has a pH of 5.5 to 7.5. Aqueous jelly composition. 2. Ammonium compound is 0.5-5 wt%,
and carboxyvinyl polymer from 0.5 to 5 wt.
The composition according to claim 1, which contains To. 3. The composition according to claim 1, wherein the ammonium compound is selected from ammonium chloride, ammonium sulfate, ammonium nitrate, ammonium phosphate, ammonium acetate, ammonium lactate, and ammonium oxalate. 4 The molecular weight of carboxyvinyl polymer is 1.00
(1. (100-3.0 old), 000) The composition according to claim 1. 5. A base whose pH is selected from alkali metal hydroxides, alkanolamines, basic amino acids, and ammonia. A composition according to claim 1 prepared by:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13074982A JPS5920217A (en) | 1982-07-27 | 1982-07-27 | Aqueous jellylike composition stably containing urea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13074982A JPS5920217A (en) | 1982-07-27 | 1982-07-27 | Aqueous jellylike composition stably containing urea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5920217A true JPS5920217A (en) | 1984-02-01 |
| JPS6241645B2 JPS6241645B2 (en) | 1987-09-03 |
Family
ID=15041714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13074982A Granted JPS5920217A (en) | 1982-07-27 | 1982-07-27 | Aqueous jellylike composition stably containing urea |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5920217A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6130567A (en) * | 1984-07-23 | 1986-02-12 | Shiseido Co Ltd | Method of stabilizing urea |
| JPS63166825A (en) * | 1986-12-27 | 1988-07-11 | Hisamitsu Pharmaceut Co Inc | Clear gel drug preparation containing urea in stable state |
| JPS63174924A (en) * | 1987-01-14 | 1988-07-19 | Toko Yakuhin Kogyo Kk | Ointment base and ointment |
| JPH01294625A (en) * | 1988-05-19 | 1989-11-28 | Hisamitsu Pharmaceut Co Inc | Antiphlogistic and analgesic external preparation |
| WO2001049283A1 (en) * | 2000-01-03 | 2001-07-12 | Karl Kraemer | Preparations for the non-traumatic excision of a nail |
| JP2005060386A (en) * | 2003-07-29 | 2005-03-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
| JP2006524199A (en) * | 2003-04-24 | 2006-10-26 | ロレアル | Cosmetic peeling method |
| EP1476131A4 (en) * | 2002-02-15 | 2007-03-07 | Hydron Technologies Inc | COMPOSITIONS AND METHODS FOR ADMINISTERING COSMETICS FOR THE SKIN |
| JP2007230943A (en) * | 2006-03-02 | 2007-09-13 | Nitto Boseki Co Ltd | Moisturizer for hands and moisturizer products for containers |
| JP2009102358A (en) * | 2003-07-29 | 2009-05-14 | Rohto Pharmaceut Co Ltd | External preparation for skin |
| JP2011074033A (en) * | 2009-09-30 | 2011-04-14 | Kobayashi Pharmaceutical Co Ltd | Pharmaceutical composition for external use |
-
1982
- 1982-07-27 JP JP13074982A patent/JPS5920217A/en active Granted
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6130567A (en) * | 1984-07-23 | 1986-02-12 | Shiseido Co Ltd | Method of stabilizing urea |
| JPS63166825A (en) * | 1986-12-27 | 1988-07-11 | Hisamitsu Pharmaceut Co Inc | Clear gel drug preparation containing urea in stable state |
| JPS63174924A (en) * | 1987-01-14 | 1988-07-19 | Toko Yakuhin Kogyo Kk | Ointment base and ointment |
| JPH01294625A (en) * | 1988-05-19 | 1989-11-28 | Hisamitsu Pharmaceut Co Inc | Antiphlogistic and analgesic external preparation |
| WO2001049283A1 (en) * | 2000-01-03 | 2001-07-12 | Karl Kraemer | Preparations for the non-traumatic excision of a nail |
| EP1476131A4 (en) * | 2002-02-15 | 2007-03-07 | Hydron Technologies Inc | COMPOSITIONS AND METHODS FOR ADMINISTERING COSMETICS FOR THE SKIN |
| JP2006524199A (en) * | 2003-04-24 | 2006-10-26 | ロレアル | Cosmetic peeling method |
| JP2005060386A (en) * | 2003-07-29 | 2005-03-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
| JP2009102358A (en) * | 2003-07-29 | 2009-05-14 | Rohto Pharmaceut Co Ltd | External preparation for skin |
| JP2007230943A (en) * | 2006-03-02 | 2007-09-13 | Nitto Boseki Co Ltd | Moisturizer for hands and moisturizer products for containers |
| JP2011074033A (en) * | 2009-09-30 | 2011-04-14 | Kobayashi Pharmaceutical Co Ltd | Pharmaceutical composition for external use |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6241645B2 (en) | 1987-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5561264B2 (en) | Hair growth composition | |
| JPH07316023A (en) | Hair tonic | |
| CN117137817B (en) | Residue removing composition, sensitive creatine facial cleanser and preparation method of sensitive creatine facial cleanser | |
| JPS6241645B2 (en) | ||
| JP2020037517A (en) | External composition containing minoxidil, and method for preventing deposition of minoxidil | |
| JP2002326913A (en) | Hair restoration composition | |
| JP7346838B2 (en) | External pharmaceutical composition | |
| US20030045503A1 (en) | Composition for the relief of joint pain and myofascial pain and method of preparing same | |
| US6977081B1 (en) | Facial cream composition containing allantoin | |
| JP5881879B1 (en) | External composition for improving acne vulgaris | |
| JP4926354B2 (en) | Topical skin preparation | |
| JPH03157311A (en) | Cosmetic for common acne | |
| JP3434635B2 (en) | How to prevent odor and discoloration of water-containing cosmetics | |
| JPH0233013B2 (en) | SOKONCHIRYOZAI | |
| DE10393402T5 (en) | Agent and toiletry or pharmaceutical composition for accelerating uptake of basic amino acids into cells | |
| CN117098525A (en) | Compositions for the care of keratin materials | |
| JP3582951B2 (en) | External preparation for skin | |
| JPH08283138A (en) | Skin cosmetic | |
| JPH08104642A (en) | Stabilized composition for injection of sodium hyaluronate | |
| JP2016193881A (en) | Topical composition for amelioration of acne vulgaris | |
| JP3836051B2 (en) | Skin external preparation containing arbutin | |
| JPH1179937A (en) | Skin lotion for pimple treatment | |
| JPS6393708A (en) | Dissolved composition of benzo-1,2,4-(thiadiazine)-1-dioxide derivative | |
| JPS61200918A (en) | Anti-inflammatory analgesic agent for external use | |
| JP2869168B2 (en) | Hair restorer and hair restoration cosmetics containing it |